Carlsmed, Inc. CARL

Company Overview

Carlsmed, Inc. (Nasdaq: CARL) is a U.S.-based medical technology company focused on personalized spine surgery solutions for patients with spinal deformities and degenerative spinal conditions. The company operates within the orthopedic medical device and spinal implant industries, developing patient-specific surgical planning platforms and implant systems intended to improve surgical precision and clinical outcomes. Carlsmed’s core commercial offering combines digital surgical planning, proprietary data analytics, and customized spinal implants produced through advanced manufacturing technologies, including 3D printing.

The company’s primary revenue drivers are its personalized spinal implant systems, surgical planning services, and related procedural solutions used by spine surgeons and healthcare systems. Carlsmed has positioned itself around the integration of artificial intelligence-enabled planning software with patient-matched implant manufacturing, which differentiates it from traditional spinal implant companies that primarily rely on standardized hardware inventories. Founded in California, the company evolved from a technology-focused startup into a commercial-stage spine platform company emphasizing data-driven personalization in complex spine procedures.

Business Operations

Carlsmed generates revenue through the commercialization of its aprevo® personalized spine surgery platform and associated procedural technologies. The company’s operations center on the design and manufacture of patient-specific implants for adult spinal deformity procedures, supported by proprietary surgical planning software and clinical workflow tools. Its business model integrates imaging analysis, preoperative planning, implant design, and manufacturing into a single platform intended to streamline surgeon decision-making and improve procedural consistency.

The company primarily operates in the United States, where it serves spine surgeons, hospitals, and healthcare providers specializing in complex spinal reconstruction. Carlsmed controls several core technological assets, including proprietary surgical planning algorithms, patient-matched implant design capabilities, and additive manufacturing processes used to produce customized implants. Publicly available information indicates the company collaborates with surgeons and clinical institutions to support product development and outcome tracking. Data regarding significant international joint ventures or large-scale overseas subsidiaries remains limited in publicly available sources.

Strategic Position & Investments

Carlsmed’s strategic direction has focused on expanding adoption of personalized spine surgery through software-enabled procedural planning and scalable implant manufacturing. The company has invested in expanding clinical evidence supporting its personalized approach, increasing surgeon adoption, and broadening commercial coverage across spine centers in the United States. Growth initiatives have included enhancing the capabilities of the aprevo® platform, improving workflow integration for surgeons, and expanding manufacturing and operational infrastructure to support increased procedural volume.

The company also operates at the intersection of medical devices, artificial intelligence-assisted healthcare planning, and additive manufacturing. Its strategic positioning reflects broader healthcare trends toward precision medicine and individualized procedural solutions. Public filings and investor materials emphasize investment in research and development, clinical validation, and data collection to strengthen payer, surgeon, and hospital adoption. Information regarding major acquisitions or extensive portfolio holdings is limited based on currently available public disclosures.

Geographic Footprint

Carlsmed is headquartered in Carlsbad, California, and its primary commercial presence is concentrated in the United States spine surgery market. The company’s operations include engineering, manufacturing coordination, clinical support, and commercialization activities centered around U.S. healthcare providers performing spinal deformity procedures. Its products are primarily marketed to domestic surgeons and hospital systems specializing in orthopedic and neurosurgical spine care.

While the company has referenced broader market opportunities beyond the United States, publicly verifiable operational data regarding large-scale international commercialization remains limited. Available public information indicates that Carlsmed’s strategic emphasis has remained focused on building market penetration within the North American spine surgery ecosystem before broader geographic expansion. Data inconclusive based on available public sources regarding material operational footprints across multiple continents.

Leadership & Governance

Carlsmed was founded by executives and medical technology professionals with experience in spinal surgery innovation and orthopedic device commercialization. The company’s leadership strategy has emphasized integrating engineering, data science, and clinical collaboration into a personalized surgery platform. Public company communications and investor materials consistently describe a focus on improving procedural predictability, patient outcomes, and surgeon workflow efficiency through technology-enabled personalization.

Key executives include:

• Mike Cordonnier – Chief Executive Officer
• Brad Lurey – Chief Financial Officer
• Dr. Antoine Tohmeh – Chief Medical Officer
• Jonathan Jaglom – Chairman of the Board

The company’s governance framework reflects a typical publicly traded medical technology structure with oversight from a board of directors and executive leadership experienced in healthcare technology, spinal implants, commercialization, and medical device operations. Public disclosures, including SEC filings, indicate ongoing emphasis on clinical validation, commercialization discipline, and scalable operational growth.